Novo Nordisk goes "on the offensive" following Trump deal that also included rival Eli Lilly, putting an exclamation point on rapidly declining GLP-1 drug prices. Experts say the unusual situation ...

Novo Nordisk announced on Monday that it is lowering costs for weight loss and diabetes drugs, weeks after it struck a deal ...

Robert Armstrong There has been a wild and hectic series of M&A deals in the pharmaceuticals industry. We are now headed for ...

Eli Lilly shares rose again Tuesday, their sixth increase in the past seven sessions. The drugmaker's market cap also closed ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump ...

The new generation of obesity medications are inducing greater weight loss than any prior pharmacotherapy. There is discussion now about how to support fat loss while protecting lean mass.“Lean mass ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite ...

Novo Nordisk announced Monday that it is significantly cutting the prices of its blockbuster GLP-1 drugs, Wegovy (for weight ...

A GLP-1/glucagon dual agonist induced significant weight loss and improved multiple cardiometabolic parameters for adults ...

Oz called the calculation "our estimate based on company numbers," referring to Lilly and Novo Nordisk, the makers of the ...